Evaluation for effects on anticancer efficacy and patient's QOL from dosage adjustment caused by skin toxicity in Panitumumab treatment for Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Registration Number
- JPRN-UMIN000015065
- Lead Sponsor
- Gifu Prefectual Tajimi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Not provided
1. Presence of severe drug allergy 2. Administration contraindication of using drugs 3. Antiplatelet or anticoagulant cannot be discontinued 4. Active infectious disease causing fever more than 38 deg C 5. Active gastrointestinal bleeding 6. Serious comorbidities (ileus, interstitial pneumonia, pulmonary fibrosis, uncontrollable diabetes, severe renal failure and liver failure etc.) 7. Pleural effusion or ascites that drainage is needed for 8. Other active malignancies those DFS is within 5 years (except for carcinoma in situ that was confirmed cured by local treatment) 9. Women of childbearing potential, women in pregnancy or lactation and patients who have desire to bear children 10. Investigator deems inappropriate to participate in the test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Quality of life of the patient, response rate, total dosage and duration of Panitumumab